摘要
Histone methyltransferase KMT2D plays a critical role as a human oncogene in prostate cancer (PCa). Dysregulated inflammatory responses and cytokine signaling are implicated in cancer progression. Furthermore, interleukin 6 (IL-6) is a pleiotropic cytokine that contributes to PCa progression; however, the association between KMT2D and IL-6 in PCa remains unclear. PCa cell proliferative potential, migratory potential, and apoptosis in vitro were determined using cell counting kit-8 (CCK-8), EdU incorporation, wound healing, and apoptosis assays. Proliferation and migratory potential were impaired and apoptosis was induced in PCa cells cultured with the conditioned medium from KMT2D-depleted cells. Cytokine array analysis showed that IL-6 was the most affected cytokine in the conditioned me-dia. KMT2D knockdown significantly downregulated the expression of IL-6 in PCa cells. What's more, proliferation and migration were also impaired and apoptosis was also induced by silencing IL-6R expression. Immunohistochemistry (IHC) and quantitative reverse transcription-polymerase chain re-action (qRT-PCR) were performed to validate the positive correlation between KMT2D and IL-6 in PCa tissue samples. Chromatin immunoprecipitation (ChIP)-PCR demonstrated that KMT2D and H3K4me1 occupied IL-6 enhancer regions and therefore, directly regulated IL-6 expression. The present study revealed that the KMT2D knockdown suppressed prostate cancer progression through the down -regulation of paracrine IL-6 signaling. These results suggest that KMT2D could be regarded as a potential new target for PCa therapy.
学科与关键词
- Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancerZhai, Qiliang; Luo, Mayao; Zhang, Yifan; Zhang, Wenqiang; Wu, Chenwei; Lv, Shidong*; Wei, Qiang*Translational Cancer Research, 2022, 11(8): 2607-+.被引 2
- The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progressionYao, Bing; Zhu, Sha; Wei, Xiyi; Chen, Ming-Kun; Feng, Yangkun; Li, Zhimin; Xu, Xinyu; Zhang, Yuwei; Wang, Yang; Zhou, Jingwan; Tang, Ningyuan; Ji, Chengjian; Jiang, Peng; Zhao, Shan-Chao*; Qin, Chao*; Feng, Ninghan*Molecular Cancer, 2022, 21(1): 119.被引 12
- SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrestWang, Chong; Wang, Tao; Li, Kang-Jing; Hu, Ling-Hong; Li, Yue; Yu, Yu-Zhong; Xie, Tao; Zhu, Sha; Fu, Du-Jiang; Wang, Yang; Zeng, Xian-Zi; Liu, Feng-Ping; Chen, Hong; Chen, Zhe-Sheng; Feng, Ning-Han*; Liu, Jinghua*; Jiang, Yong*; Zhao, Shan-Chao*Cancer Letters, 2023, 579: 216464.
